Technical Report: TLD Transition Technical Brief

Tenofovir/Lamivudine/Dolutegravir (TLD) is a new and innovative antiretroviral drug (ARV) therapy used to treat HIV. The Government of South Africa is preparing to transition eligible people living with HIV from Tenofovir/Emtricitabine/Efavirenz (TEE), the fixed dose combination of antiretroviral medicines currently used as first line therapy in the management of the disease, to this exciting new treatment option.